PURPOSE: To evaluate the effectiveness and safety of interactive transperineal brachytherapy under biplane ultrasound and fluoroscopic guidance in patients with localized prostate cancer. METHODS AND MATERIALS: Brachytherapy using 125I or 103Pd radioactive seeds either alone or in combination with adjunctive external beam radiotherapy (XRT) was administered to 490 patients at a single institution. Post-treatment follow-up included clinical assessment of disease status, assays of serum prostate-specific antigen (PSA) levels and documentation of treatment-related symptoms and complications. RESULTS: Actuarial disease-free survival at 5 yr was 79% (95% CI, 71-85%), and the 5-yr actuarial rate of local control was 98% (95% CI, 94-99%). Post-treatment PSA nadir and pretreatment PSA level were found to be significant predictors of disease-free survival. In patients with a PSA nadir < 0.5 ng/ml, 5-yr disease-free survival was 93% (95% CI, 84-97%), compared with 25% (95% CI, 5-53%) in patients whose PSA nadir was 0.5-1.0 ng/ml and 15% (95% CI, 3-38) in patients with a PSA nadir > 1.0 ng/ml. Brachytherapy was well tolerated with few post-treatment complications. CONCLUSION: A broad range of patients with localized prostate cancer can benefit from transperineal brachytherapy with minimal morbidity. A post-treatment PSA nadir below 0.5 ng/ml provides a useful prognostic indicator of favorable long-term outcome.
PURPOSE: To evaluate the effectiveness and safety of interactive transperineal brachytherapy under biplane ultrasound and fluoroscopic guidance in patients with localized prostate cancer. METHODS AND MATERIALS: Brachytherapy using 125I or 103Pd radioactive seeds either alone or in combination with adjunctive external beam radiotherapy (XRT) was administered to 490 patients at a single institution. Post-treatment follow-up included clinical assessment of disease status, assays of serum prostate-specific antigen (PSA) levels and documentation of treatment-related symptoms and complications. RESULTS: Actuarial disease-free survival at 5 yr was 79% (95% CI, 71-85%), and the 5-yr actuarial rate of local control was 98% (95% CI, 94-99%). Post-treatment PSA nadir and pretreatment PSA level were found to be significant predictors of disease-free survival. In patients with a PSA nadir < 0.5 ng/ml, 5-yr disease-free survival was 93% (95% CI, 84-97%), compared with 25% (95% CI, 5-53%) in patients whose PSA nadir was 0.5-1.0 ng/ml and 15% (95% CI, 3-38) in patients with a PSA nadir > 1.0 ng/ml. Brachytherapy was well tolerated with few post-treatment complications. CONCLUSION: A broad range of patients with localized prostate cancer can benefit from transperineal brachytherapy with minimal morbidity. A post-treatment PSA nadir below 0.5 ng/ml provides a useful prognostic indicator of favorable long-term outcome.
Authors: Stefan Machtens; Rolf Baumann; Jörn Hagemann; Antje Warszawski; Andreas Meyer; Johann H Karstens; Udo Jonas Journal: World J Urol Date: 2006-08 Impact factor: 4.226
Authors: A Jain; A Deguet; I Iordachita; G Chintalapani; S Vikal; J Blevins; Y Le; E Armour; C Burdette; D Song; G Fichtinger Journal: Med Image Anal Date: 2010-08-14 Impact factor: 8.545
Authors: A Gabriella Wernicke; Michael Shamis; Weisi Yan; Samuel Trichter; Albert M Sabbas; Yevgenia Goltser; Paul J Christos; Jennifer S Brennan; Bhupesh Parashar; Dattatreyudu Nori Journal: Urology Date: 2012-05 Impact factor: 2.649
Authors: David R Holmes; Brian J Davis; Christopher C Goulet; Torrence M Wilson; Lance A Mynderse; Keith M Furutani; Jon J Camp; Richard A Robb Journal: Brachytherapy Date: 2014-06-21 Impact factor: 2.362
Authors: Pedro J Prada; Javier Anchuelo; Ana Garcia Blanco; Gema Paya; Juan Cardenal; Enrique Acuna; Maria Ferri; Andres Vazquez; Maite Pacheco; Jesica Sanchez Journal: Int Braz J Urol Date: 2016 Jan-Feb Impact factor: 1.541